Cookies on the BTG website

We use cookies to ensure that we give you the best experience on our website.

If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the BTG website.

Find out more

Continue

Investors

Utilities: Print; Email

Email to a friend

* Required

Regulatory Announcements

Please find below a list of our regulatory announcements, organised in chronological order.

30 April 2013 BTG plc: Total Voting Rights and Share Capital
15 April 2013 BTG plc: Notification of Major Interest in Shares
15 April 2013 BTG plc: Notification of Major Interest in Shares
12 April 2013 BTG plc: Varisolve^® NDA accepted for full review by FDA
04 April 2013 BTG plc: Close Period Update
02 April 2013 BTG plc: Block Listing Return
28 March 2013 BTG plc: Total Voting Rights and Share Capital
21 March 2013 Director’s interests in the shares of BTG plc (“BTG” or “the Company”)
28 February 2013 BTG plc: Total Voting Rights and Share Capital
04 February 2013 BTG plc: Varisolve^® NDA submitted to the FDA
31 January 2013 BTG plc: Total Voting Rights and Share Capital
31 January 2013 BTG plc: Interim Management Statement
02 January 2013 BTG plc: Total Voting Rights and Share Capital

20 December 2012 BTG plc: Total Voting Rights and Share Capital
17 December 2012 BTG plc: Total Voting Rights and Share Capital
14 December 2012 BTG plc: Notification of Major Interest in Shares
11 December 2012 BTG plc: Appointment of Non-executive Director
11 December 2012 BTG plc: US FDA approves expanded ZYTIGA^® indication for treatment of metastatic castration-resistant prostate cancer
10 December 2012 BTG plc: Total Voting Rights and Share Capital
30 November 2012 BTG plc: Total Voting Rights and Share Capital
26 November 2012 BTG plc: Total Voting Rights and Share Capital
20 November 2012 BTG plc: Total Voting Rights and Share Capital
20 November 2012 BTG plc: Janssen announces that ZYTIGA^® has received a positive opinion in the EU for treating chemo-naïve mCRPC patients
19 November 2012 Full data from pivotal Phase III trials of Varisolve^® PEM presented at the 26th Annual Congress of the American College of Phlebology
15 November 2012 BTG plc: Total Voting Rights and Share Capital
12 November 2012 Directors’ Interests in the shares of BTG plc
08 November 2012 BTG plc: Interim Results
31 October 2012 BTG plc: Total Voting Rights and Share Capital
25 October 2012 BTG plc: Total Voting Rights and Share Capital
19 October 2012 BTG plc: Notification of Results
18 October 2012 BTG plc: Total Voting Rights and Share Capital
17 October 2012 BTG plc: Block Listing Return
11 October 2012 BTG plc: Total Voting Rights and Share Capital
03 October 2012 BTG plc: Total Voting Rights and Share Capital
03 October 2012 BTG plc: Close Period Update
28 September 2012 BTG plc: Total Voting Rights and Share Capital
21 September 2012 BTG plc: Directorship Change
18 September 2012 BTG plc: Total Voting Rights and Share Capital
28 August 2012 BTG plc: Additional Listing
09 August 2012 BTG plc: Notification of Major Interest in Shares
08 August 2012 BTG plc: Notification of Major Interest in Shares
08 August 2012 BTG Announces Data from Phase IIb Study of AZD9773
01 August 2012 BTG plc: Notification of Major Interest in Shares
31 July 2012 BTG plc: Total Voting Rights and Share Capital
26 July 2012 Directors’ Interests in the Shares of BTG plc
25 July 2012 BTG plc: Total Voting Rights and Share Capital
18 July 2012 BTG plc: Total Voting Rights and Share Capital
17 July 2012 BTG plc: Results of 2012 Annual General Meeting
17 July 2012 BTG plc: Interim Management Statement
16 July 2012 BTG plc: Annual Information Update
06 July 2012 BTG plc: Total Voting Rights and Share Capital
19 June 2012 BTG plc: Annual Report and Accounts 2012
12 June 2012 BTG plc: Applications submitted to FDA and EMA for approval of Lemtrada^™ (alemtuzumab) for Multiple Sclerosis
11 June 2012 BTG plc: Directorship Notification under Listing Rule 9.6.14
08 June 2012 Directors’ Interests in the shares of BTG plc
31 May 2012 BTG plc: Total Voting Rights and Share Capital
29 May 2012 BTG plc: Notification of change of TIDM
25 May 2012 BTG to present at the Jefferies Global Healthcare Conference
24 May 2012 BTG plc: Total Voting Rights and Share Capital
22 May 2012 BTG plc: Notification of Major Interest in Shares
21 May 2012 BTG plc: Directors' Interests in the Shares of BTG plc
21 May 2012 BTG plc: Final Results
30 April 2012 BTG plc: Total Voting Rights and Share Capital
23 April 2012 BTG Announces Positive Results from Second US Pivotal Phase III Trial of Varisolve^®
12 April 2012 BTG plc: Total Voting Rights and Share Capital
04 April 2012 BTG plc: Close Period Update
02 April 2012 BTG plc: Block Listing Return
29 March 2012 BTG plc: Directorship Notification under Listing Rule 9.6.14
08 March 2012 BTG plc: ZYTIGA^® (abiraterone acetate) second Phase III trial unblinded
29 February 2012 BTG plc: Additional Listing
14 February 2012 BTG plc: Directorate Change Amendment
31 January 2012 BTG plc: Total Voting Rights and Share Capital
30 January 2012 BTG Announces Positive Data from First US Phase III Trial of Varisolve^®
26 January 2012 BTG plc: Total Voting Rights and Share Capital
25 January 2012 BTG plc: Interim Management Statement
23 January 2012 BTG plc: Notification of Major Interest in Shares
18 January 2012 BTG plc: Voraxaze^® (glucarpidase) receives US regulatory approval
17 January 2012 BTG plc: Directorship Notification under Listing Rule 9.6.14
09 January 2012 BTG plc: Total Voting Rights and Share Capital
06 January 2012 BTG plc: Total Voting Rights and Share Capital

07 December 2011 BTG plc: Total Voting Rights and Share Capital
07 December 2011 BTG plc: Voraxaze^® (glucarpidase) licensed to Ohara Pharmaceuticals in Japan
30 November 2011 BTG plc: Total Voting Rights and Share Capital
30 November 2011 BTG plc: Notification of Major Interest in Shares
21 November 2011 BTG plc: Total Voting Rights and Share Capital
17 November 2011 BTG plc: Interim Results
16 November 2011 BTG plc: Total Voting Rights and Share Capital
11 November 2011 BTG plc: Garry Watts to succeed Dr John Brown as non-executive Chairman
08 November 2011 BTG plc: Total Voting Rights and Share Capital
04 November 2011 BTG plc: Total Voting Rights and Share Capital
01 November 2011 BTG plc: Directorate Change
31 October 2011 BTG plc: Total Voting Rights and Share Capital
19 October 2011 BTG plc: Additional Listing
12 October 2011 BTG plc: Notification of Major Interest in Shares
05 October 2011 BTG plc: Total Voting Rights and Share Capital
05 October 2011 BTG plc: Block Listing Return
05 October 2011 BTG plc: Close Period Update
03 October 2011 BTG plc: Total Voting Rights and Share Capital
30 September 2011 BTG plc: Total Voting Rights and Share Capital
28 September 2011 BTG plc: Notification of Major Interest in Shares
20 September 2011 BTG plc: FDA accepts Biologics License Application file for Voraxaze^® (glucarpidase) and grants Priority Review
19 September 2011 BTG plc: Total Voting Rights and Share Capital
12 September 2011 BTG plc: Total Voting Rights and Share Capital
07 September 2011 BTG plc: ZYTIGA^™ (abiraterone acetate) approved in the EU
06 September 2011 BTG plc: Total Voting Rights and Share Capital
02 September 2011 BTG plc: Total Voting Rights and Share Capital
01 September 2011 Directors’ Interests in the shares of BTG plc
05 August 2011 BTG plc: Notification of Interest in Shares
03 August 2011 BTG plc: Notification of Major Interest in Shares
01 August 2011 BTG plc: Notification of Major Interest in Shares
29 July 2011 BTG plc: Total Voting Rights and Share Capital
26 July 2011 BTG plc: Total Voting Rights and Share Capital
25 July 2011 Directors' Interests in the Shares of BTG plc
20 July 2011 BTG plc: Results of 2011 Annual General Meeting
20 July 2011 BTG plc: Annual General Meeting and Interim Management Statement
14 July 2011 BTG plc: Annual Information Update
14 July 2011 BTG plc: Notification of Major Interest in Shares
11 July 2011 BTG plc: Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada^™) in Multiple Sclerosis Reported
06 July 2011 BTG Acquires US Marketing Rights to Wellstat’s Investigational Antidote for 5-FU Overexposure
30 June 2011 BTG plc: Total Voting Rights and Share Capital
22 June 2011 BTG plc: Annual Report and Accounts 2011
15 June 2011 BTG plc: Additional Listing
03 June 2011 BTG plc: Total Voting Rights and Share Capital
02 June 2011 Directors’ Interests in the shares of BTG plc
25 May 2011 BTG plc: Final Results
18 May 2011 BTG plc: Notification of Results
16 May 2011 BTG plc: Notification of Major Interest in Shares
13 May 2011 BTG plc: AstraZeneca ends CM-3 development and option agreement
12 May 2011 BTG plc: Notification of Major Interest in Shares
03 May 2011 BTG plc: ZYTIGA^™ (abiraterone acetate) Approved in the US
26 April 2011 BTG plc: Notification of Major Interest in Shares
05 April 2011 BTG plc: Notification of Major Interest in Shares
05 April 2011 BTG plc: Block Listing Return
05 April 2011 BTG plc: Close Period Update
31 March 2011 BTG plc: Total Voting Rights and Share Capital
17 March 2011 BTG plc: Notification of Major Interest in Shares
16 March 2011 BTG plc: Total Voting Rights and Share Capital
15 March 2011 BTG plc: Notification of Major Interest in Shares
15 March 2011 BTG plc: Notification of Major Interest in Shares
11 March 2011 BTG plc: DEFEND-1 study of otelixizumab in type 1 diabetes did not meet primary endpoint
11 February 2011 BTG plc: Notification of Major Interest in Shares
07 February 2011 BTG plc: Notification of Major Interest in Shares
02 February 2011 BTG plc: Notification of Major Interest in Shares
02 February 2011 BTG plc: Notification of Major Interest in Shares
01 February 2011 BTG plc: Notification of Major Interest in Shares
01 February 2011 BTG plc: Notification of Major Interest in Shares
01 February 2011 BTG plc: Notification of Major Interest in Shares
01 February 2011 BTG plc: Appointment of Joint Corporate Broker
31 January 2011 BTG plc: Notification of Major Interest in Shares
31 January 2011 BTG plc: Notification of Major Interest in Shares
31 January 2011 BTG plc: Total Voting Rights and Share Capital
28 January 2011 BTG plc: Notification of Major Interest in Shares
28 January 2011 Offer Update: Admission of New BTG Shares
27 January 2011 Offer Update: Scheme Effective
27 January 2011 BTG plc: Interim Management Statement
26 January 2011 BTG plc: Notification of Major Interest in Shares
24 January 2011 Offer Update: Court sanction of the Scheme of Arrangement and timetable update
06 January 2011 Offer Update: Result of BTG Shareholder Meeting

21 December 2010 BTG plc: New Drug Application Submitted in the US and Marketing Authorisation Application Filed in the EU for Abiraterone Acetate
10 December 2010 Offer update: Posting of Scheme Document
30 November 2010 BTG plc: Total Voting Rights and Share Capital
29 November 2010 BTG plc: Appointment of Non-executive Director
25 November 2010 BTG plc: Total Voting Rights and Share Capital
24 November 2010 BTG plc: Total Voting Rights and Share Capital
19 November 2010 Recommended acquisition by BTG plc of Biocompatibles International plc
04 November 2010 BTG plc: Interim Results
29 October 2010 BTG plc: Total Voting Rights and Share Capital
28 October 2010 BTG plc: Notification of Major Interest in Shares
25 October 2010 BTG plc: AstraZeneca initiates Phase IIb study for AZD9773 (CytoFab^™) as a treatment for severe sepsis
20 October 2010 BTG plc: Notification of Results
15 October 2010 BTG plc: Genzyme reports positive data on alemtuzumab
04 October 2010 BTG plc: Block Listing Return
04 October 2010 BTG plc: Total Voting Rights and Share Capital
16 September 2010 BTG plc: First Varisolve^® US Phase III Trial Initiated
13 September 2010 BTG plc: Notification of Major Interest in Shares
10 September 2010 BTG plc: Abiraterone Acetate Meets Pre-Determined Criteria in Metastatic Prostate Cancer Study
01 September 2010 Directors’ Interests in the shares of BTG plc
31 August 2010 BTG plc: Agreement with Nycomed US Inc.
30 July 2010 BTG plc: Appointment of Non-executive Director
21 July 2010 Directors’ Interests in the Shares of BTG plc
16 July 2010 BTG plc: Resolutions Passed at the Annual General Meeting
16 July 2010 BTG plc: Appointment of Joint Financial Adviser and Corporate Broker
14 July 2010 BTG plc: Director’s retirement
13 July 2010 BTG plc: Results of 2010 Annual General Meeting
13 July 2010 BTG plc: Annual General Meeting and Interim Management Statement
12 July 2010 BTG plc: Annual Information Update 2010
05 July 2010 BTG plc: Total Voting Rights and Share Capital
22 June 2010 BTG plc: Notification of Major Interest in Shares
17 June 2010 BTG plc: Notification of Major Interest in Shares
17 June 2010 Directors' Interests in the shares of BTG plc
15 June 2010 BTG plc: Notification of Submission of Documents to the UK Listing Authority
02 June 2010 BTG plc: Notification of Major Interest in Shares
02 June 2010 Directors’ Interests in the shares of BTG plc
21 May 2010 BTG plc: Preliminary Results
10 May 2010 BTG plc: Notification of Major Interest in Shares
07 May 2010 BTG plc: Notification of Major Interest in Shares
04 May 2010 BTG plc: Total Voting Rights and Share Capital
19 April 2010 BTG plc: Notification of Results
16 April 2010 BTG plc: Notification of Major Interest in Shares
14 April 2010 BTG plc: Notification of Major Interest in Shares
08 April 2010 BTG plc: Block Listing Return
01 April 2010 BTG plc: Close Period Update
01 April 2010 BTG plc: Total Voting Rights and Share Capital
16 March 2010 BTG plc: Director’s appointment
11 March 2010 BTG plc: Notification of Major Interest in Shares
01 March 2010 BTG plc: Total Voting Rights and Share Capital
18 February 2010 BTG plc: Notification of Major Interest in Shares
12 February 2010 BTG plc: Notification of Major Interest in Shares
04 February 2010 BTG Receives First European Regulatory Approval for DigiFab^™
29 January 2010 BTG plc: Total Voting Rights and Share Capital
21 January 2010 BTG Commences Phase IIa Study of Pleneva^™ for Multiple Sclerosis
21 January 2010 BTG plc: Interim Management Statement
07 January 2010 BTG plc: Notification of Major Interest in Shares
06 January 2010 BTG plc: Notification of Major Interest in Shares

18 December 2009 BTG Licenses ReGel^® to Allergan for use in diseases of the eye
15 December 2009 BTG plc: Notification of Major Interest in Shares
10 December 2009 BTG plc: Notification of Major Interest in Shares
27 November 2009 BTG plc: Notification of Major Interest in Shares
18 November 2009 BTG plc: Notification of Major Interest in Shares
05 November 2009 BTG plc: Interim Results
02 November 2009 BTG plc: Total Voting Rights and Share Capital
01 October 2009 BTG plc: Notification of Results
01 October 2009 BTG plc: Block Listing Return
01 October 2009 BTG plc: Total Voting Rights and Share Capital
24 September 2009 BTG plc: Campath^® Meets Primary Endpoint in Phase III Combination Therapy Trial for Chronic Lymphocytic Leukemia
02 September 2009 BTG plc: Notification of Major Interest in Shares
02 September 2009 Directors’ Interests in the shares of BTG plc
01 September 2009 BTG plc: Total Voting Rights and Share Capital
28 August 2009 BTG Sells HySolv^™ Technology to Major Pharmaceutical Company
26 August 2009 Directors’ Interests in the shares of BTG plc
17 August 2009 BTG Collaborator Onyx Gains Approval to Progress Oncology Compound into Clinical Development
03 August 2009 Directors’ Interests in the Shares of BTG plc
03 August 2009 BTG plc: Total Voting Rights and Share Capital
29 July 2009 BTG plc: AstraZeneca to Progress CytoFab^™ into Phase IIb Study
23 July 2009 Directors' Interests in the Shares of BTG plc
16 July 2009 BTG plc: Annual Information Update 2009
15 July 2009 BTG plc: Annual General Meeting and Interim Management Statement
15 July 2009 BTG plc: Results of 2009 AGM
09 July 2009 BTG plc: Notification of Major Interest in Shares
07 July 2009 BTG plc: Total Voting Rights and Share Capital
19 June 2009 BTG plc: Notification of Submission of Documents to the UK Listing Authority
03 June 2009 BTG plc: Notification of Major Interests in Shares
29 May 2009 BTG plc: Total Voting Rights and Share Capital
14 May 2009 BTG plc: Preliminary Results
08 May 2009 BTG plc: Notification of Major Interests in Shares
05 May 2009 BTG plc: Notification of Major Interests in Shares
05 May 2009 BTG plc: Notification of Major Interests in Shares
04 May 2009 BTG plc: Notification of Results
30 April 2009 BTG plc: Total Voting Rights and Share Capital
21 April 2009 Block Listing Return
02 April 2009 BTG plc: Close Period Update
31 March 2009 BTG plc: Total Voting Rights and Share Capital
23 January 2009 BTG plc: Director/PDMR Shareholding
22 January 2009 BTG plc: Interim Management Statement
12 January 2009 BTG plc: Notification of Major Interests in Shares
07 January 2009 BTG plc: Notification of Major Interests in Shares
02 January 2009 BTG plc: Total Voting Rights and Share Capital

11 December 2008 BTG plc: Notifiable Share Interest
11 December 2008 BTG plc: Notifiable Share Interest
10 December 2008 BTG plc: Director’s Share Dealing
08 December 2008 BTG plc: Notifiable Interests In Shares
08 December 2008 BTG plc: Notification of Major Interests in Shares
05 December 2008 BTG plc: Notification of Major Interests in Shares
05 December 2008 BTG Plc: Notification of Major Interests in Shares
04 December 2008 BTG plc: Completion of the Acquisition of Protherics PLC
01 December 2008 BTG plc: Total Voting Rights and Share Capital
20 November 2008 BTG Licensee Cougar Biotechnology Initiates Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Breast Cancer
17 November 2008 BTG plc : Notification of Major Interests in Shares
12 November 2008 BTG plc: Interim Results for the Six Months Ended 30 September 2008
07 November 2008 Full Results of Varisolve^® US Phase II Safety Study to be Presented at ACP
07 November 2008 BTG licenses novel anticancer compound to Onyx Pharmaceuticals
05 November 2008 BTG plc: Result of EGM
28 October 2008 BTG plc to Announce its Interim Results on 12 November 2008
23 October 2008 BTG plc: Final Phase II Results of Campath^® Multiple Sclerosis Study Published
17 October 2008 BTG plc ("BTG") and Protherics PLC ("PROTHERICS"): Offer Update - Intended Date of Posting of Offer Documents
17 October 2008 BTG plc ("BTG") and Protherics PLC ("PROTHERICS"): Offer Update - Posting of Scheme Document/Receipt of Letters of Intent
01 October 2008 Block Listing Return
30 September 2008 BTG plc: Total Voting Rights and Share Capital
22 September 2008 Directors’ Interests in the Shares of BTG plc
18 September 2008 18 September 2008: Recommended All Share Offer by BTG plc for Protherics plc
29 August 2008 BTG plc: Total Voting Rights and Share Capital
06 August 2008 BTG plc: Tolerx Initiates Dosing of Otelixizumab in a Phase III Clinical Trial in Type 1 Diabetes
31 July 2008 BTG plc: Total Voting Rights and Share Capital
22 July 2008 BTG plc: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer
16 July 2008 BTG plc: Annual General Meeting and Interim Management Statement
16 July 2008 BTG plc: Results of 2008 AGM
11 July 2008 Annual Information Update 2008
01 July 2008 BTG plc: Total Voting Rights and Share Capital
16 June 2008 Block Listing Return
16 June 2008 BTG plc: Notification of Submission of Documents to the UK Listing Authority
06 June 2008 BTG Reports Successful Completion of Treatments in Varisolve^® US Phase II Safety Study
04 June 2008 BTG plc: Acquisition of Protez Pharmaceuticals by Novartis
30 May 2008 BTG plc: Total Voting Rights and Share Capital
29 May 2008 Directors’ Interests in the Shares of BTG plc
19 May 2008 BTG plc: Preliminary Results for the Year Ended 31 March 2008
12 May 2008 BTG plc: Notice of Results
10 April 2008 BTG Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnoea Patients
02 April 2008 BTG plc: Close Period Update
31 March 2008 BTG plc: Total Voting Rights and Share Capital
18 March 2008 BTG plc: Notifiable Interests in Shares
17 March 2008 BTG plc: Positive Interim Report of Varisolve^® Phase II Safety Study to be Presented at SIR 2008 Scientific Meeting
06 March 2008 BTG Initiates Clinical Study of Novel Multiple Sclerosis Treatment
29 February 2008 BTG plc: Total Voting Rights and Share Capital
30 January 2008 BTG plc Commences First Clinical Study of Novel Migraine Treatment
24 January 2008 BTG plc: Interim Management Statement
17 January 2008 Senexis Raises £3.7 Million from the Wellcome Trust and BTG to Further Develop its Small Molecule Alzheimer's Compounds

04 December 2007 BTG plc Appoints Dr John Brown as Chairman Designate
30 November 2007 BTG plc: Total Voting Rights and Share Capital
19 November 2007 BTG plc: Notification of submission of documents to the UK listing authority
12 November 2007 BTG plc: Directors’ Interests in the shares of BTG plc
07 November 2007 BTG plc: Interim Results for the Six Months Ended 30 September 2007
31 October 2007 BTG plc: Total Voting Rights and Share Capital
24 October 2007 BTG Licensee Tolerx Forms Collaboration with GlaxoSmithKline to Develop and Commercialise TRX4
10 October 2007 BTG plc: Notifiable Interests In Shares
02 October 2007 BTG plc: Notifiable Interests in Shares
28 September 2007 BTG plc: Total Voting Rights and Share Capital
28 September 2007 BTG plc: Board Changes
28 September 2007 BTG plc: Close Period Update
26 September 2007 BTG plc: Campath^® commences pivotal phase III trial in multiple sclerosis
20 September 2007 BTG plc: Campath^® approved for first-line use in Adult Leukemia
14 August 2007 BTG plc: Notifiable Interests in Shares
31 July 2007 Directors’ Interests in the shares of BTG plc
30 July 2007 BTG plc Block Listing Application
19 July 2007 Directors’ Interests in the Shares of BTG plc
18 July 2007 BTG plc: Results of 2007 AGM
18 July 2007 BTG plc: 2007 Annual General Meeting and Interim Management Statement
13 July 2007 Directors’ Interests in the Shares of BTG plc
12 July 2007 Annual Information Update 2007
29 June 2007 BTG plc – Total Voting Rights and Share Capital
20 June 2007 Notification of Submission of Documents to the UK Listing Authority
15 June 2007 Directors' Interests in the Shares of BTG plc
01 June 2007 BTG plc – Total Voting Rights and Share Capital
25 May 2007 Preliminary Results Statement
30 April 2007 BTG plc – Total Voting Rights and Share Capital
19 April 2007 BTG Signs Agreement with Novacea and KuDOS for AQ4N
13 April 2007 BTG Continues Physical Sciences Divestment Programme Granting Two Licenses to Technology Patents Worth Up to $46m
02 April 2007 BTG plc: Close Period Update
30 March 2007 Block Listing Six Monthly Return
05 March 2007 Notification of Interest in Shares
28 February 2007 BTG plc – Total Voting Rights and Share Capital
27 February 2007 BTG Licensee Cougar Biotechnology Presents Positive Data on Prostate Cancer Compound at ASCO Symposium
20 February 2007 BTG Acquires Novel Opioid Agonist for Post-Operative Pain Control from CLL Pharma
13 February 2007 BTG plc Announces that on 13 February 2007 it Received the Following Major Shareholding Notification
22 January 2007 BTG PLC: NOTIFIABLE INTERESTS IN SHARES
22 January 2007 BTG's Plevitrexed Shows Promising Efficacy and Tolerability in a Phase I/II study
19 January 2007 BTG plc - Total Voting Rights and Share Capital

22 December 2006 BTG licenses haemofiltration device patents to Fresenius Medical Care
22 December 2006 BTG plc – Total Voting Rights and Share Capital
21 December 2006 BTG PLC: NOTIFICATION OF MAJOR INTERESTS IN SHARES
13 December 2006 Results of European Phase III Randomised Controlled Trial Comparing Varisolve ^® with Surgery or Sclerotherapy Published in Phlebology
01 December 2006 BTG PLC: NOTIFICATION OF MAJOR INTERESTS IN SHARES
30 November 2006 BTG: PLC: Notification of Major Interests in Shares
24 November 2006 Notification of Submission of Documents to the UK Listing Authority
09 November 2006 BTG plc: Interim Results for the Six Months Ended 30 September 2006
03 November 2006 BTG PLC : Notification of Major Interests in Shares
03 November 2006 BTG PLC : Notification of Major Interests in Shares
03 November 2006 BTG PLC : Notification of Major Interests in Shares
23 October 2006 BTG PLC: Notification of Major Interests in Shares
11 October 2006 BTG PLC : Notification of Major Interests in Shares
02 October 2006 Block Listing Six Monthly Return
27 September 2006 BTG Appoints Peter Chambré as Non-Executive Director
25 September 2006 BTG Completes Sale of RFID Patent Portfolio
23 August 2006 Directors’ Interests in the shares of BTG plc
17 August 2006 BTG Licensee TolerRx, Inc. Raises $35.6m to Develop TRX4; Phase III Pivotal Trial in Type 1 Diabetes Planned to Commence in 2006
16 August 2006 BTG Sells Online Navigation Tracking Patents
31 July 2006 BTG PLC: Notification of Major Interests in Shares
26 July 2006 BTG PLC: 2006 ANNUAL GENERAL MEETING
26 July 2006 BTG plc: Results of AGM
26 July 2006 BTG plc: 2006 AGM Statement
25 July 2006 BTG plc: Notification of Major Interests in Shares
17 July 2006 BTG PLC: Notification of Major Interests in Shares
12 July 2006 Annual Information Update 2006
04 July 2006 BTG PLC: Notification of Major Interests in Shares
28 June 2006 Directors' Interests in the Shares of BTG plc
27 June 2006 BTG PLC: Application to the London Stock Exchange
23 June 2006 Notification of Submission of Documents to the UK Listing Authority
19 June 2006 Directors’ Interests in the Shares of BTG plc
19 June 2006 BTG to commence US phase II clinical safety study of Varisolve®
05 June 2006 BTG PLC : Notification of Major Interests in Shares
25 May 2006 BTG reports preliminary results for the year ended 31 March 2006
08 May 2006 BTG plc: Notification Of Major Interests In Shares
31 March 2006 BTG plc: Close Period Update
31 March 2006 BTG Sells Teleshuttle Patent Rights To Twintech E.U.
03 March 2006 BTG PLC : Notification of Major Interests in Shares
10 February 2006 BTG Appoints Piper Jaffray as Joint Financial Adviser and Joint Broker
06 February 2006 BTG Grants QRSciences Option to Acquire NQR Patents
02 February 2006 BTG Licenses Alzheimer's Compounds To Senexis And Co-Invests
£1 Million With The Wellcome Trust

24 November 2005 Directors' Interests in the Shares of BTG plc
17 November 2005 Directors' Interests in the shares of BTG plc
10 November 2005 BTG plc: Interim Results
07 November 2005 BTG plc Releases Financial Statement Information For The Year to 31 March 2005 Restated Under IFRS
03 October 2005 BTG plc: Close Period Update and sale of RFID patents
05 September 2005 BTG PLC: Notification of Major Interests in Shares
29 August 2005 BTG and Collegium Pharmaceutical to Develop a Modified Release Asthma Product
15 August 2005 BTG Licenses Fundamental Online Navigation Tracking Patents to Netflix
28 July 2005 BTG PLC: 2005 Annual General Meeting
13 July 2005 BTG plc: Varisolve^{^®} given FDA approval to recommence US clinical trials
04 July 2005 Directors' Interests in the shares of BTG plc
28 June 2005 BTG plc: Notification of Submission of Documents to the UK Listing Authority
28 June 2005 Notification of Submission of Documents to the UK Listing Authority
24 June 2005 BTG plc: Publication of positive data from TRX4 type 1 diabetes study
26 May 2005 Directors' Interests in the shares of BTG plc
26 May 2005 BTG plc appoints Christine Soden as Chief Financial Officer
26 May 2005 BTG plc: Preliminary Results and Strategic Review
26 May 2005 BTG presents a live audio webcast to announce Preliminary results for the year ended 31 March 2005
23 May 2005 BTG PLC: Notification of Major Interests in Shares
19 May 2005 BTG settles two-part hip cup litigation
11 May 2005 BTG PLC: Notification of Major Interests in Shares
10 May 2005 BTG plc: Close Period Statement - Update
28 April 2005 BTG PLC : Notification of Major Interests In shares
21 April 2005 BTG plc: Update on Varisolve^{^®}
07 April 2005 BTG PLC: Notification of Major Interests in Shares
01 April 2005 BTG plc: CLOSE PERIOD UPDATE
09 February 2005 Statement regarding share price movement
27 January 2005 Update on Varisolve^{^®}

Latest news

latest news

Read our latest news and find out about our recent achievements and company milestones.

Press releases

Keep up to date

You can keep up to date with our news by subscribing to our email alerts. Alternatively keep up to date with changes to our website by subscribing to one of our news feeds.